Recent Press Releases

01-21-2010 -
BioNumerik Initiates Treatment of Patients in Global Phase III Clinical Trial of Tavocept™ to Confirm Substantial Survival Increases Previously Observed in Most Common Type of Lung Cancer

European Journal of Clinical & Medical Oncology Publishes Meta-Analysis of Phase II and Phase III Trials Supporting Tavocept’s Potential to Increase Lung Cancer Survival

07-17-2008 - BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept™ Clinical Trial

03-18-2008 - BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept™

02-07-2008 - BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin®